These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26166682)

  • 1. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
    Brønden A; Naver SV; Knop FK; Christensen M
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1493-503. PubMed ID: 26166682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
    Davis PN; Ndefo UA; Oliver A; Payton E
    Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
    Brønden A; Knop FK; Christensen MB
    Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albiglutide: a review of its use in patients with type 2 diabetes mellitus.
    Blair HA; Keating GM
    Drugs; 2015 Apr; 75(6):651-63. PubMed ID: 25777969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].
    Scheen AJ
    Rev Med Liege; 2015 Apr; 70(4):207-14. PubMed ID: 26054173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
    Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes.
    Matthews JE; Reinhardt RR; Carr MC
    Postgrad Med; 2016 May; 128(4):391-7. PubMed ID: 27043162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
    Trujillo JM; Nuffer W
    Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
    Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
    Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
    Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
    Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
    Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
    Rosenstock J; Reusch J; Bush M; Yang F; Stewart M;
    Diabetes Care; 2009 Oct; 32(10):1880-6. PubMed ID: 19592625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albiglutide for the management of type 2 diabetes.
    Rendell MS
    Expert Rev Endocrinol Metab; 2018 Jan; 13(1):1-8. PubMed ID: 30063441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
    Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
    St Onge EL; Miller SA
    Expert Opin Biol Ther; 2010 May; 10(5):801-6. PubMed ID: 20367248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albiglutide for the treatment of type 2 diabetes.
    Muscogiuri G; Gastaldelli A
    Drugs Today (Barc); 2014 Oct; 50(10):665-78. PubMed ID: 25374965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.